Table 2.
Change of NLR and PLR at different stages of treatment
| Value | Mean ± sd | P-value |
|---|---|---|
| NLR | 3.26±1.36 | |
| NLR1 | 2.87±1.60 | 0.016 |
| NLR2 | 8.98±9.96 | <0.01 |
| NLR3 | 4.27±3.70 | 0.499 |
| NLR1 | 2.87±1.60 | |
| NLR2 | 8.98±9.96 | <0.01 |
| NLR3 | 4.27±3.70 | 0.012 |
| NLR2 | 8.98±9.96 | |
| NLR3 | 4.27±3.70 | <0.01 |
| PLR | 151.50±60.01 | |
| PLR1 | 182.18±94.30 | <0.01 |
| PLR2 | 308.49±252.23 | <0.01 |
| PLR3 | 193.58±106.35 | 0.026 |
| PLR1 | 182.18±94.30 | |
| PLR2 | 308.49±252.23 | <0.01 |
| PLR3 | 193.58±106.35 | 0.508 |
| PLR2 | 308.49±252.23 | |
| PLR3 | 193.58±106.35 | <0.01 |
Abbreviations: NLR, neutrophil-to-lymphocyte ratio at diagnosis; PLR, platelet-to-lymphocyte ratio at diagnosis; sd, standard deviation; NLR1, neutrophil-to-lymphocyte ratio after one cycle of chemotherapy; NLR2, neutrophil-to-lymphocyte ratio after thoracic radiotherapy; NLR3, neutrophil-to-lymphocyte ratio at progression; PLR1, platelet-to-lymphocyte ratio after one cycle of chemotherapy; PLR2, platelet-to-lymphocyte ratio after thoracic radiotherapy; PLR3, platelet-to-lymphocyte ratio at progression.